Daiichi Sankyo’s once-daily edoxaban shows comparable efficacy and superiority for the principal safety endpoint compared to warfarin in a Phase 3 study for the treatment of symptomatic VTE and prevention of its recurrence
Daiichi Sankyo announced results from the global phase 3 Hokusai-VTE…
1 September 2013 | By Daiichi Sankyo
Daiichi Sankyo announced results from the global phase 3 Hokusai-VTE study...